The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

Inclusion Criteria: * Subject has provided informed consent * Subjects are at least 18 years of age or older at the time of screening * Female subjects must not be pregnant or breast-feeding * Female subjects of child-bearing potential with a negative urine pregnancy test and using at least one form of contraception (abstinence allowed) * Subjects must have a confirmed diagnosis of ARCI (divided phenotypically into ARCI-LI or ARCI-CIE), EI or NS (by genotype or willingness to be genotyped) * Subjects must be clinically judged to be immunocompetent. * Subjects will have no allergy to secukinumab or components of the product. * Subjects will have normal baseline laboratory testing (CMP, CBC, HIV negative, hepatitis B, C negative, QuantiFERON®-TB gold negative) * Subjects must have an erythema score of at least 18 on IASI and an IASI-E score of 12 (at least moderate severity of erythema) at baseline Exclusion Criteria: * Subjects who are unable to give informed consent or assent. * Subjects without a confirmed diagnosis ARCI, EI, or NS. * Subjects who have a known allergy to secukinumab. * Female subjects who are pregnant, considering becoming pregnant, or will breastfeed. * Subjects who have prior biologic use targeting IL-17A/IL-17 receptor A or IL-12/IL-23 or who have prior use of TNF-alpha blockers. * Subjects who have used a systemic retinoid within one month prior to initiation. * Subjects who have used topical retinoids or keratolytics within one week prior to initiati…